Phase 3 Vasculitis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been recently diagnosed with, or have had a return of, a condition called granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)
- A specific blood test (ELISA) has come back positive for certain markers linked to these conditions (called MPO or PR3 antibodies)
- Your kidneys are being seriously affected by your condition, shown by a kidney function test result below a certain level (and this low level must be new, not something that has been stable for more than 3 months)
- A kidney biopsy or urine test has shown signs of active kidney damage caused by your condition
Who may not be able to join:
- You have a different type of vasculitis (such as eosinophilic granulomatosis with polyangiitis, IgA vasculitis, cryoglobulinemic vasculitis, or rheumatoid vasculitis)
- A blood test or kidney biopsy has shown a different type of kidney disease not related to GPA or MPA
- You have been diagnosed with lupus or Sjögren's syndrome
- You have been on dialysis for more than 21 days just before joining the trial, or you have previously had a kidney transplant
- You are under 18 years old
- You are pregnant at the time of screening
- You have already received significant amounts of certain treatments (specific chemotherapy or steroid medications) in the 28 days before joining the trial (confirm with trial site for exact details)
- You have a long-term viral infection such as HIV, hepatitis B, or hepatitis C
- You have an untreated hidden tuberculosis infection
- You currently have an active infection
- You have another health condition that the trial doctor feels would make it unsafe for you to take the medications used in this trial (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: David Massicotte-Azarniouch, MD, MSc, The Ottawa Hospital
Phone: 613-738-8400
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Pilot trial: percent adherence to intervention regimen; Full-scale trial: Rate of serious infection
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.